Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

Background Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric allergy and immunology 2021-07, Vol.32 (5), p.980-991
Hauptverfasser:	Nieto García, Antonio, Garriga‐Baraut, Teresa, Plaza Martín, Ana María, Nieto Cid, María, Torres Borrego, Javier, Folqué Giménez, María del Mar, Lozano Blasco, Jaime, Bosque García, Montserrat, Moreno‐Galarraga, Laura, Tortajada‐Girbés, Miguel, Rivas Juesas, Cristina, Penín Antón, María, Caballero‐Rabasco, María Araceli, Gaboli, Mirella, López Neyra, Alejandro, Navarro Morón, Juan, Freixa Benavente, Andrea, Valdesoiro Navarrete, Laura, Ballester Asensio, Esther, Sanz Santiago, Verónica, Romero García, Raquel, Gimeno Díaz de Atauri, Álvaro, Valenzuela Soria, Alfredo, Sánchez Mateos, Mercedes, Batlles Garrido, José, Andrés Martín, Anselmo, Campos Alonso, Elena, Aragón Fernández, Carmen, Vázquez Rodríguez, Elena, Martínez Pardo, Luz, del‐Río Camacho, Genoveva, Mazón Ramos, Ángel, Kalaycı, Ömer
Format:	Artikel
Sprache:	eng
Schlagworte:	adolescents Adverse events Allergies Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use anti‐asthmatic agents Asthma Asthma - drug therapy Child children humanized monoclonal antibodies Humans Immunoglobulin E Monoclonal antibodies Observational studies observational study omalizumab Omalizumab - adverse effects Omalizumab - therapeutic use Patients Pediatrics real life Retrospective Studies severe asthma Teenagers Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date. Methods ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients
ISSN:	0905-6157 1399-3038
DOI:	10.1111/pai.13484